港股異動丨雲頂新耀-B升超10% 新藥臨牀試驗申請在中國獲批
雲頂新耀-B(1952.HK)快速拉昇升超10%,現報21.3港元創反彈新高,總市值69億港元。消息上,公司宣佈中國國家藥品監督管理局藥品審評中心已批准在中國啟動zetomipzomib(澤託佐米)治療活動性狼瘡性腎炎(LN)的2b期PALIZADE試驗的新藥臨牀試驗(IND)申請。澤託佐米是一款新型、同類首創、選擇性免疫蛋白酶體抑制劑,用於治療包括狼瘡性腎炎、系統性紅斑狼瘡在內的一系列自身免疫性疾病。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.